Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory Phase II trial of FK228 (depsipeptide) in androgen-independent metastatic prostate cancer with rising PSA
2005-001576-13Phase 2Completed
- Sponsor
- Gloucester Pharmaceuticals
- Start
- Apr 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of romidepsin in prostate cancer (PCa), sponsored by Gloucester Pharmaceuticals. Primary endpoint: Objective disease control rate. Started Apr 2005; status: completed.
02
Drugs
romidepsin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2005-001576-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001576-13.